AKT Genetic Alteration Cell Panel (ATCC® TCP-1029)

Permits and Restrictions

View Permits View Restrictions

Components ATCC CRL-2321 HCC1143
ATCC CRL-7245 Hs 343.T
ATCC HTB-20 BT-474
Applications This panel is useful for AKT pathway research, as well as for developing pan-AKT inhibitors or isoform-specific AKT inhibitors as anti-cancer therapeutics.
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Comments AKT is a serine–threonine protein kinase that is expressed as three isoforms (AKT1, -2 and -3). AKT activation is initiated by translocation to the plasma membrane, which is mediated by a receptor tyrosine kinase-PI3K pathway. Activated AKT phosphorylates many key proteins, such as glycogen synthase kinase 3 and FOXOs, and regulates cell survival, proliferation and other cellar processes. Amplification of AKT1 and AKT2 has been discovered in a variety of common tumor types.  AKT1 is linked to tumor cell survival and growth, whereas AKT2 is linked to tumor invasiveness.

The AKT genetic alteration cell panel (ATCC TCP-1029) is composed of eight human tumor cell lines from common cancer types that carry ATK gene copy number changes. The AKT1 and AKT2 gene alteration status of each cell line has been sequenced and validated by ATCC. This panel is useful for AKT pathway research, as well as for developing pan-AKT inhibitors or isoform-specific AKT inhibitors for anti-cancer therapeutics.
Product Format frozen
Storage Conditions LN vapor (less than -130┬░C) only
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • For-profit customers must obtain a research use license agreement from the Contributor prior to shipment.
  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation

Unless the Purchaser has a separate license agreement with The University of Texas M. D. Anderson Cancer Center (“Institution”), the ATCC Material is subject to the following restrictions:

  1. The ATCC Material (and any Modifications, Unmodified Derivatives and/or Progeny thereof) may not be used (1) for commercial purposes or Commercial Use by any Purchaser, or (2) by for-profit or commercial entities for any purpose, provided, however, that ATCC Material that is purchased from ATCC as deoxyribonucleic acid and/or ribonucleic acid or nucleotide chains of any length (hereinafter, “Nucleic Acids”) may be used for internal research purposes by any Purchaser of Nucleic Acids;
  2. Purchaser may not transfer ATCC Materials, Modifications, Unmodified Derivatives, or Progeny to any for-profit entity or commercial entity; and
  3. Purchaser may not use ATCC Materials (or any Modifications, Unmodified Derivatives and/or Progeny thereof) in connection with any research, collaboration or other activities involving a third party that is a commercial entity or for-profit entity.

The restrictions set forth above are in addition to the restrictions set forth in the ATCC Material Transfer Agreement. Capitalized terms have the meanings set forth in the ATCC Material Transfer Agreement unless otherwise indicated above.

For instructions on how to obtain a license from Institution, please contact Dustin J. Romine, M.A. at the Institution Office of Technology Commercialization via email at dromine@mdanderson.org.

Purchaser acknowledges and agrees that ATCC will send Purchaser’s contact information and order details to Institution’s Office of Technology Commercialization.